RFA-AI-28-002-Full-Announcement.html

HTML file 169 KB Posted

Attached to
HIV/AIDS Clinical Trials Network Laboratory Centers (UM1 Clinical Trial Required)
Opportunity number
RFA-AI-28-002
Issued by

About this file

This is a Notice of Funding Opportunity (NOFO) and Request for Applications (RFA) for HIV/AIDS Clinical Trials Network Laboratory Centers. The National Institute of Allergy and Infectious Diseases (NIAID) and partner institutes seek to fund up to four Laboratory Centers (LCs) supporting distinct HIV/AIDS Clinical Trials Networks focused on adult therapeutics, maternal/adolescent/pediatric populations, HIV prevention, and immune-based prevention research. The funding opportunity (RFA-AI-28-002) supports a 7-year project period with an estimated total commitment of $29 million across the four awards. Applications are due February 9, 2027, with earliest start dates beginning March 9, 2027. This is a cooperative agreement (UM1 mechanism) requiring applicants to propose clinical trials and providing substantial federal programmatic involvement beyond typical grant stewardship.

The LCs will oversee site-affiliated clinical and specialized laboratories (immunology, pharmacology, virology), ensure protocol-specified laboratory testing reliability, implement data management systems, select and approve laboratories for network participation, and promote state-of-the-art assays. Eligible applicants include higher education institutions, nonprofits with or without 501(c)(3) status, for-profit organizations, state and local governments, tribal governments, and faith-based/community-based organizations. Applications must address specific subsections covering laboratory center overview, scientific leadership and governance, laboratory science contributions, laboratory selection and quality assurance, specimen management, data management, operational oversight, communication/harmonization, and training/mentoring. All PD/PIs require eRA Commons accounts and ORCID registration. Applicants should contact the relevant NIH institute (NIAID, NHLBI, NIA, NICHD, NIDCR, NIDDK, NIDA, or NIMH) with scientific or financial questions. The opportunity is assigned to multiple CFDA programs including 93.855 (Allergy and Infectious Diseases Research), 93.310 (Trans-NIH Research Support), 93.242 (Mental Health Research Grants), and others.

RFA-AI-28-002-Full-Announcement.html

Text of this file

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)

Office of AIDS Research (OAR)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Aging (NIA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

Applicants should carefully note which ICOs participate in this announcement and refer to NIH Institute, Center, and Office Grants & Funding Profiles for ICO-specific missions, interest areas, priorities, and funding considerations.

Funding Opportunity Title

HIV/AIDS Clinical Trials Network Laboratory Centers (UM1 Clinical Trial Required)

Activity Code

UM1 Research Project with Complex Structure Cooperative Agreement

Announcement Type

Reissue of

RFA-AI-19-001

Related Notices

Check for any recent Notices of NIH Policy Changes that may impact application requirements.

Funding Opportunity Number (FON)

RFA-AI-28-002

Companion Funding Opportunity

RFA-AI-28-001

, UM1

Research Project with Complex Structure Cooperative Agreement

RFA-AI-28-003

RFA-AI-28-004

Number of Applications

See Part 2, Section III. 3. Additional Information on Eligibility.

Assistance Listing Number(s)

93.8RP, 93.HDR, 93.310, 93.242, 93.853, 93.AGR, 93.DA1, 93.HL6, 93.KRC, 93.DE1

Funding Opportunity Purpose

The purpose of the notice of funding opportunity (NOFO) is to support HIV/AIDS Clinical Trials Network Laboratory Centers (LCs). The LCs will provide a framework for laboratory leadership, structure and activities that contribute to the HIV/AIDS Clinical Trials Networks research agendas and execute the laboratory component of Network trials, in compliance with applicable regulatory standards.

Funding Opportunity Goal(s)

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.

Key Dates

Posted Date

November 20, 2026

Open Date (Earliest Submission Date)

February 09, 2027

Application Due Dates
Review and Award Cycles
New
Renewal / Resubmission / Revision (as allowed)

AIDS - New/Renewal/Resubmission/Revision, as allowed

Scientific Merit Review
Advisory Council Review
Earliest Start Date

March 09, 2027

March 09, 2027

Not Applicable

July 2027
October 2027

December 2027

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

March 10, 2027

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide, except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts).

Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.
Use the NIH ASSIST system to prepare, submit and track your application online.
Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.
Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.

Table of Contents

Part 1. Overview Information Key Dates Part 2. Full Text of Announcement Section I. Notice of Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV. Application and Submission Information Section V. Application Review Information Section VI. Award Administration Information Section VII. Agency Contacts Section VIII. Other Information

Part 2. Full Text of Announcement

Section I. Notice of Funding Opportunity Description

Network Scope and Structure The National Institute of Allergy and Infectious Diseases (NIAID) and its Institute, Center, and Office (ICO) partners will support four Clinical Trials Networks with unique research agendas that will conduct HIV/AIDS prevention, treatment and implementation science research improving uptake of evidence-based strategies across the lifespan:

HIV/AIDS Adult Therapeutics Clinical Trials Network
HIV/AIDS Maternal, Adolescent and Pediatric Clinical Trials Network
HIV Prevention Clinical Trials Network
Immune-Based Prevention Clinical Trials Network

Each HIV/AIDS Clinical Trials Network is composed collectively of the following clinical trials infrastructure designed to support a complex research agenda:

RFA-AI-28-001 - HIV/AIDS Clinical Trials Network Leadership and Operations Centers (LOCs) RFA-AI-28-002 - HIV/AIDS Clinical Trials Network Laboratory Centers (LCs) – this notice of funding opportunity (NOFO) RFA-AI-28-003 - HIV/AIDS Clinical Trials Network Statistical and Data Management Centers (SDMCs) RFA-AI-28-004 - HIV/AIDS Clinical Trials Network Clinical Trials Units (CTUs) While the emphasis of each Network is on clinical trials, clinical research studies that are not NIH-defined clinical trials are also in scope when undertaken to support the program. For this NOFO, the term "clinical study" refers to both clinical trials and clinical research studies, and "clinical trial" is used to refer to a clinical trial only.

NIAID plans to fund one LC award for each Network.

Each Clinical Trials Network will have an Executive Management Committee (EMC), established by the LOC, to coordinate the activities of the Network's LOC, LC and SDMC.

NIAID is responsible for the oversight and safety of all study participants in clinical trials funded by NIAID, and will provide NIAID-convened Data and Safety Monitoring Boards (DSMBs) to monitor clinical trials. NIAID will provide additional support services for Network trials under an Investigational New Drug (IND) or Investigational Device Exemption (IDE).

The Division of AIDS (DAIDS) Clinical Laboratory Oversight Team (DCLOT) will contribute to, and oversee, the implementation of harmonized DAIDS clinical lab-related guidelines, standards, and requirements. DCLOT will oversee DAIDS-funded contractual laboratory quality assurance resources to ensure that Network laboratories perform according to good clinical laboratory practices (GCLP).

Laboratory Center Specific Responsibilities The LC will oversee site-affiliated clinical as well as central specialized laboratories (e.g., immunology, pharmacology, virology), to monitor and ensure the reliability of protocol-specified laboratory testing. In addition, the aims of the LC include:

Support sample integrity from time of collection to final testing or storage;
Use appropriate laboratory data capturing management and tracking systems;
Implement an approach to select, determine readiness, and approve laboratories to participate in trials;
Promote the use of state-of-the-art laboratory assays in trials; and
Serve as a mechanism to increase capacity and capabilities to meet NIAID future unanticipated needs related to emerging infectious diseases.

The LC is responsible for expert leadership and scientific oversight across all laboratory aspects of the Clinical Trials Network's (CTNs) research agenda, serving as a central force in advancing high-quality, coordinated scientific work. In close collaboration with protocol teams, it shapes the design and execution of laboratory components within studies, while also developing comprehensive guidance materials and delivering targeted training to ensure consistency and excellence. Its role extends to the evaluation, qualification, and ongoing oversight of participating laboratories–including clinical, central, and specialized facilities affiliated with study sites–ensuring adherence to NIAID, Clinical Laboratory Improvement Amendments (CLIA), Good Clinical Laboratory Practice (GCLP), and external quality assurance standards, as applicable.

A defining feature of the LC is its implementation of a flexible and cost-effective laboratory infrastructure. By integrating clinic-based, central, regional, and specialized laboratories, it enables rapid protocol activation and responsiveness to evolving research priorities. This structure supports the harmonization of laboratory processes across networks, promoting efficiency and comparability of data.

Working in coordination with protocol teams, the SDMC, NIAID quality assurance programs, and site partners, the LC ensures the integrity and reliability of specimen management systems, laboratory data platforms, regulatory compliance, and clinical quality management practices. It supports centralized testing for studies that span multiple CTNs, facilitates the storage and accessibility of specimens for future research, and drives the advancement of innovative and point-of-care assays suited for both clinical and implementation studies.

The LC also plays a critical role in enabling sponsor audits and strengthening research accountability. At the same time, it contributes to workforce development by fostering the training and mentorship of the next generation of HIV laboratory scientists, reinforcing long-term capacity and scientific leadership in the field.

The Research Agendas for the four Networks are as follows:

1. HIV/AIDS Adult Therapeutics Clinical Trials Network – Responsible for supporting the advancement of therapeutics research toward the treatment and cure of adults living with HIV including implementation science and clinical research to improve the management of HIV-related co-morbidities, coinfections and aging. Key aspects to this research agenda include:

Implementation Science - strategies to adapt, deliver, and expand the reach, scale-up, and sustainability of evidence-based treatment for HIV and HIV-associated diseases.
Novel and Durable Interventions for HIV – strategies to achieve durable HIV suppression and improve treatment outcomes for adults living with HIV.
Anti-retroviral (ART)-Free Remission (HIV Cure) - strategies to eradicate HIV or sustain virologic remission through immune-based interventions.
Complications and Non-Infectious Comorbidities – strategies to improve the prevention, treatment and management of high-impact co-morbidities in PWH (e.g., neurocognitive, substance use disorders, cardiovascular diseases, lung diseases, diabetic and related metabolic and endocrine conditions, kidney, urologic and hematologic disease, oropharyngeal complications, aging associated conditions).
Viral Hepatitis - novel treatment strategies for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.
Tuberculosis - novel therapeutics and combination treatments for drug-sensitive and -resistant tuberculosis (TB).

Additionally, this Network will be responsible for the clinical research infrastructure to support early-stage pilot trials of novel products and approaches; opportunities for intensive sampling of potential tissue reservoirs of HIV; and specialized laboratory capabilities for virologic and immunologic analyses.

2. HIV/AIDS Maternal, Adolescent, and Pediatric Clinical Trials Network – Responsible for advancing research to generate the evidence base on novel, innovative therapies, interventions, methods, and strategic approaches for HIV and HIV-associated conditions in infants, children, adolescents, and pregnant/postpartum women, integrating implementation science across the product development lifecycle to speed their adoption and scale-up. Key aspects to this research agenda include:

Implementation Science - strategies to adapt, deliver and scale evidence-based interventions that optimize prevention for pregnant and breastfeeding women, strengthen maternal antiretroviral therapy (ART), tailor infant prophylaxis, and expand early and repeat HIV testing for breastfeeding infants and children.
HIV Treatment and Prevention Innovations - antiretroviral drug and regimen innovations in appropriate long-acting (or pediatric-friendly oral) formulations for pediatric and maternal populations and infant postnatal prophylaxis.
ART-Free Remission (HIV Cure) - strategies to achieve sustained virologic remission in pediatric populations, including strategies initiated in the immediate newborn period.
Treatment and Prevention of Tuberculosis and Other HIV-associated Co-Infections - new drugs and regimens for treatment and prevention of drug-sensitive and resistant TB disease, both pulmonary and extrapulmonary (including central nervous system [CNS]); address treatment needs for congenital syphilis, viral hepatitis (B and C), and other important HIV-associated co-occurring infections.
Brain and Mental Health and Other HIV-associated Comorbidities - Neuroprotective and neurotoxic effects of ART to preserve neurocognitive development and mental health in infants, children, and adolescents. Evaluate novel preventive and therapeutic approaches for other high-priority diseases and co-occurring conditions

3. HIV Prevention Clinical Trials Network – Responsible for advancing products and strategies to meet the needs of populations vulnerable to HIV acquisition including adults, adolescents and pregnant women, through the integration of biomedical, socio-behavioral and structural prevention strategies, in partnership with implementing agencies and organizations. Key aspects to this research agenda include:

Implementation Science – strategies to optimize deployment of and improve access to biomedical and socio-behavioral evidence-based interventions for HIV prevention.
Integrated Prevention Strategies - integration of socio-behavioral research to optimize HIV prevention outcomes tailored to the population and context, to improve HIV treatment uptake and adherence, retention in care, and reduction of HIV risk.
Novel Biomedical HIV Prevention and Delivery Systems - strategies and delivery methods that meet the needs of varied populations and help address the challenges of adherence. Multipurpose technologies (MPTs) – products designed to simultaneously protect against multiple sexual and reproductive health issues and potentially medications to treat or prevent other health conditions.
Intersection of HIV and Other Sexually Transmitted Infections (STIs) - prevention and treatment strategies to address interaction between HIV and STIs.

4. Immune-Based Prevention Trials Network – Responsible for the discovery and advancement of immune-based strategies to protect against HIV infection and associated infectious diseases, including TB and STIs, through Phase 1–3 clinical trials designed to answer key immunologic research questions to inform future candidate design, define correlates of protection, and identify safe and efficacious preventative regimens. Key aspects to this research agenda include:

Antibody-Mediated Prevention for HIV - design and conduct Phase 1–3 trials of passive immunization strategies.
Induced-Immunity for Prevention of HIV Acquisition - evaluate immunogens, immune modulators and adjuvants; and combinations of immunogens with antiretroviral drugs and other HIV prevention modalities. Conduct rapid, iterative "discovery medicine" trials to evaluate novel immunogens and adjuvants.
Analytical Treatment Interruption (ATI) Strategies - studies in PWH to evaluate viral control to inform HIV immune-based prevention approaches and immunotherapy development.
Immune-based Prevention Strategies Against Other HIV-associated Infectious Diseases - evaluate interventions against other infectious diseases (e.g., TB and STIs) and how these diseases may influence the safety and effectiveness of HIV prevention approaches.
Integration of Implementation and Behavioral Science Research - integration across all stages of immune-based product development and evaluation, assessing acceptability and mode of intervention.
Determinants of Immune Function and Intervention Effectiveness - evaluate how the microbiome, diet and environmental exposures share or alter immune function and the effectiveness of prevention interventions.

Other Research Areas: Each Network may have the opportunity to contribute to the research agenda for support of the development of strategies, interventions, and products for the rapid response against other/emerging infectious diseases (not listed above) of public health importance and to implement clinical trials in support of this agenda. The research agenda for those efforts will be developed post-award through cross-network, joint leadership efforts in conjunction with NIAID and other NIH staff.

Core and Protocol Funds Funding to carry out the Network's research agenda falls into two categories:

Core Funds: initial fixed-base funding for infrastructure and salary support that is not protocol-specific. NIAID will provide core funds directly to the LOC, LC, SDMC and network-affiliated CTUs on an annual basis.

Protocol Funds (PF): support to conduct protocols, including protocol-specific infrastructure or other requirements needed to conduct protocols at a clinical research site. PF varies annually, depending on costs of ongoing protocols. NIAID anticipates providing PF directly to the LOC, LC, SDMC and Network-affiliated CTUs on an annual basis.

The LOC will estimate PF needs for the network (salary and non-salary PF) based on communications with the LC, SDMC, and CTUs/CRSs and submit an annual budget request to NIAID.

Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this NOFO.

Application Types Allowed

New

Renewal - Renewals of RFA-AI-19-001

The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.

Clinical Trial?

Required: Only accepting applications that propose clinical trial(s).

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

NIAID and partner components intend to commit an estimated total of $29M to fund 4 awards in FY2028.

Award Budget

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Award Project Period

The project period must be 7 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions - Includes all types
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education

Nonprofits Other Than Institutions of Higher Education

Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

Small Businesses
For-Profit Organizations (Other than Small Businesses)

Local Governments

State Governments
County Governments
City or Township Governments
Special District Governments
Indian/Native American Tribal Governments (Federally Recognized)
Indian/Native American Tribal Governments (Other than Federally Recognized)

Federal Governments

Eligible Agencies of the Federal Government

U.S. Territory or Possession

Other

Independent School Districts

Public Housing Authorities/Indian Housing Authorities

Native American Tribal Organizations (other than Federally recognized tribal governments)

Faith-based or Community-based Organizations

Regional Organizations

Foreign Organizations/Foreign Collaborations

Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.

Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

Required Registrations

Applicant Organizations Applicant organizations must complete and maintain the following registrations as described in the How to Apply - Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications for additional information System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Foreign organizations must obtain a NATO Commercial and Government Entity (NCAGE) Code (in lieu of a CAGE code) in order to register in SAM. Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.

eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
Grants.gov – Applicants must have an active SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. Obtaining an eRA Commons account can take up to 2 weeks.

All PD(s)/PI(s) must be registered with ORCID. The personal profile associated with the PD(s)/PI(s) eRA Commons account must be linked to a valid ORCID ID. For more information on linking an ORCID ID to an eRA Commons personal profile see the ORCID topic in our eRA Commons online help.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide.

2. Cost Sharing This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement NIH Grants Policy Statement Section 1.2 Definition of Terms.

3. Additional Information on Eligibility Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Section IV. Application and Submission Information

1. Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice, or other notice from NIH Guide for Grants and Contracts). Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Page Limitations All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed, with the following additional instructions:

The Research Strategy must consist of the following sub-sections with the indicated page limits:

Sub-section A. Overview of the Proposed Laboratory Center, one required - 12 pages Sub-section B. Scientific Leadership, Structure and Governance, one required - 6 pages Sub-section C. Laboratory Science and Contribution to the Network Research Agenda, one required - 30 pages Sub-section D. Laboratory Selection, Testing Capabilities and Quality Assurance, one required - 12 pages Sub-section E. Specimen Management and Access, one required - 6 pages Sub-section F. Network Data Management, one required - 6 pages Sub-section G. Oversight of Laboratory Operations, one required - 6 pages Sub-section H. Communication, Collaboration and Harmonization, one required - 6 pages Sub-section I. Training and Mentoring, one required - 6 pages

Instructions for Application Submission

The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO.

SF424(R&R) Cover All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

SF424(R&R) Other Project Information

SF424(R&R) Senior/Key Person Profile All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Within the Common Forms for Biographical Sketch and NIH Biographical Sketch Supplement, highlight the following:
The relative experiences of the PD(s)/PI(s) in leading and managing a Laboratory Center for multi-center clinical trials in a complex structure.
The expertise of applicable key personnel in working with commercial off-the-shelf (COTS) clinical trial management systems including Electronic Data Capture (EDC) systems.

R&R Budget All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Only request Core Funds for the initial fixed-base funding, infrastructure and salary support that is not protocol-specific (e.g., administrative and management support, community education and engagement structures and activities, clinical quality management activities, record retention).

Do not request Protocol Funds (PF). PF includes protocol-specific personnel salary, participant recruitment and retention, protocol required tests and evaluations, participant reimbursement, community education and engagement structures and activities, and protocol specimen shipment and storage).

R&R Subaward Budget

PHS 398 Cover Page Supplement

PHS 398 Research Plan All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Specific Aims: Describe the scientific aims of the Laboratory Center (LC). Each application in response to this NOFO must address only the research agenda of one HIV/AIDS Clinical Trials Network and must state which one of the four HIV/AIDS Clinical Trials Networks the LC proposes to support.

Research Strategy: The Research Strategy section must consist of subsections A-I as designated below.

Sub-section A. Overview of the Proposed Laboratory Center Provide a high-level overview of the overall approach of the LC in support of the affiliated network's research priorities and ensuing scientific agenda, and describe the approach to accomplishing these goals, including a description of the LC structure/composition, and coordination and integration with the LOC, SDMC and CTUs/CRSs.

For renewal applications: Progress Report should be included in sub-section A.

Sub-section B. Scientific Leadership, Structure and Governance

Describe in detail the LC structure, including plans for a staffing structure that capitalizes on the individual strengths of key personnel and other staff to achieve the goals of the LC (e.g., clinical pathologists, medical technologists, regulatory experts, laboratory science experts). Tables, diagrams, flow charts or organizational charts are strongly recommended. Provide an organization chart showing key personnel for leadership or decision-making positions in the LC. Provide plans to ensure continuity/succession for Leadership roles.
Describe the approach to governance of the LC, including establishment of decision-making entities, their composition, roles, responsibility and authority. Do not name or contact potential members who are not already key personnel in the application or provided Letters of Support.
Explain the processes to establish, review and execute competing scientific priorities and how to review and address changing needs, identify and coordinate changing resources, and evaluate and discontinue unproductive or unneeded activities.

Sub-section C. Laboratory Science and Contribution to the Network Research Agenda

Describe the key scientific research priority areas of the appropriate network; highlight the laboratory research needed to support these scientific areas; provide a history of past similar support; and discuss knowledge gaps and future opportunities.
Describe the plans and approach to obtain in a timely manner access to laboratory science expertise as well as specialized, state-of-the-art laboratory testing capabilities (e.g., diagnostics, immunology, microbiology, pharmacology, virology etc.) to meet protocol testing needs. Describe in detail the capabilities of identified specialized laboratories.
Describe the proposed process for coordination and integration with the network's scientific committees and protocol teams to contribute to sound protocol design (e.g., schedule of laboratory evaluations, choice of study endpoints) and inform on issues related to laboratory test feasibility, capability and capacity.
Describe the plans to provide sites and laboratories with protocol-associated guidance materials (e.g., laboratory manual), support tools (e.g., worksheets), and training suitable to different types of studies and locations of enrolled participants (e.g., applicable to implementation research).
Describe the plans and approaches to support the development, optimization, and evaluation of state-of-the art assays using diverse specimens for implementation in trial protocols and ancillary studies, while fostering intellectual and material collaborations among clinical and laboratory scientists to advance technology and enable clinically useful information and sound product advancement decisions.

Sub-section D. Laboratory Selection, Testing Capabilities, Quality Assurance and Oversight

Describe the approach for implementing an efficient, flexible, and cost-effective laboratory structure that allows for rapid activation of study protocols and is responsive to changing needs. Include the process for identifying, qualifying, selecting and approving testing laboratories. Indicate the types of laboratories and their testing capabilities.
Describe the approach, considerations and processes, including coordination with NIAID-funded laboratory quality oversight resources to exercise oversight of trial-supporting laboratories to ensure the reliability and integrity of protocol-specified laboratory testing and standards of laboratory operations, allowing for approval of registrational studies by U.S. and non-U.S. regulatory entities, as well as the ability to inform on product development decisions.
Describe the approach for coordinating and harmonizing laboratory oversight activities when other Networks or NIH Institutes jointly participate in the conduct of the same protocol.
Describe the approach to determining the required level of assay qualification or validation when assays are used as primary endpoints in: (1) non-Investigational New Drug (IND) trials, (2) IND trials where laboratory data will be used for regulatory submission and approval, and (3) IND trials (e.g., discovery medicine) where laboratory data are used for iterative product development.
Describe the approach and plan for quality management for LC activities needed to achieve and maintain compliance with ICHE6, 21 CFR part 11, Good Documentation Practice (GDP), and other standards (e.g., NIAID, Clinical Laboratory Improvement Amendments (CLIA), Good Laboratory Clinical Practice (GLCP), etc.) in meeting regulatory compliance.

Sub-section E. Specimen Management and Access

Describe how the LC will collaborate with protocol teams, CTU and/or CRS PD(s)/PI(s) and the SDMC to support reliable chain of custody and tracking of samples from point of acquisition to final testing or storage destination. Describe the tracking of Material Transfer Agreements (MTAs). Include a discussion on shipping challenges into and out of a country, if applicable, and how these may be addressed.
Describe how the LC will implement reliable and cost effective local and centralized short-and long-term storage of study samples.
Describe how the LC will collaborate with the network LOC and SDMC to promote timely access to stored specimens and associated data for future research by network investigators and by the broader scientific community.

Sub-section F. Network Data Management Describe how the LC will coordinate with the SDMC to ensure the implementation of a validated and verifiable laboratory data management system that allows for the capture and export of laboratory test results according to regulatory standards, as well as ensure the timeliness of laboratory data export to the network SDMC.

Sub-section G. Oversight of Laboratory Operations Describe the approach, processes and tools for providing complete, effective and efficient oversight of all aspects of LC operations, including oversight of the specialty laboratories.

Sub-section H. Communication, Collaboration and Harmonization

Describe the plans to communicate and collaborate with other awarded LCs and other NIH-funded research groups to achieve efficient utilization of resources, harmonization in areas such as laboratory approval processing, assay costing, sample acquisition and test processes, as well as centralized specialized testing to ensure harmonization of such testing in support of studies put forward by the awarded LOCs.
Provide plans for data workflows and coordination with the SDMC, as appropriate, to support timely interim analyses and reporting, including controlled unblinding procedures that preserve trial integrity while enabling efficient product iteration.
Describe the plans to share data from completed studies.

Sub-section I. Training and Mentoring

Describe how the training needs of LC staff will be determined (e.g., new methodologies, technological advancements, regulatory requirements), implemented and evaluated.
Provide the plans for promoting mentorship and involvement of the next generation of biomedical leaders in clinical laboratory science.

Letters of Support:

Provide appropriate letters of support necessary to demonstrate the support of collaborators who have a significant role in the application. Note that letters establishing intra-network and cross-network collaborations are not necessary.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide.

Other Plan(s):

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

A Data Management and Sharing Plan (DMS Plan) is required for any NIH-funded or conducted research that will generate scientific data. Applicants must submit the DMS Plan at the time of application using the NIH DMS Plan Format Page. The DMS Plan must address the elements in the structured format. Where the DMS Plan Format Page requires a "Yes or No" response, no additional narrative is allowed.

Appendix: Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply - Application Guide.

No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.

PHS Human Subjects and Clinical Trials Information When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply - Application Guide, with the following additional instructions:

Other Requested Information For Renewal applications with ongoing clinical studies, applicants must include a list of all ongoing clinical studies and/or the unique ClinicalTrials.gov identifiers. All information must be combined in one single attachment using the filename "Ongoing Clinical Studies". If appropriate, please indicate for each study the NIAID Division of AIDS (DAIDS).

If you answered "Yes" to the question "Are Human Subjects Involved?" on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information All instructions in the How to Apply - Application Guide must be followed with the following additional instructions:

Although applicants must be prepared for clinical trials, definite plans for such involvement will not be possible at time of application. A Study Record MUST not be completed.

Delayed Onset Study Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

All Applications must add and complete the Delayed Onset Study record and must check box "Anticipated Clinical Trial?".

Study Title: use "Multiple Delayed-Onset Studies" Justification Attachment: Indicate each clinical study protocol developed during the project period will be subject to approval through a procedure that involves an initial concept submission and subsequent review by the HIV/AIDS Clinical Trials Network. If the concept receives approval, the next stage will be development of the protocol, which also must undergo review and approval prior to implementation through the HIV/AIDS Clinical Trials Network.

PHS Assignment Request Form

3. Unique Entity Identifier and System for Award Management (SAM) See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times Part I. contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the How to Apply – Application Guide.

5. Intergovernmental Review (E.O. 12372) This initiative is not subject to intergovernmental review.

6. Funding Restrictions All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement Section 7.9.1 Selected Items of Cost.

Awards issued under this notice of funding opportunity (NOFO) will be incrementally funded awards and may be issued for project periods of up to 7 years. Multi-year funded grants will not be allowed.
Grants awarded under this NOFO will not be provided the authority to automatically extend the final budget period one time to 12 months beyond the original project period end date shown in the Notice of Award. All extensions, including the first extension, will require prior approval. Please note a 7-year grant does not qualify for a no-cost extension.
Progress and financial reporting will be required and reviewed annually. All funds must be expended within the approved project period.

7. Other Submission Requirements and Information Applications must be submitted electronically following the instructions described in the How to Apply - Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply - Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Mandatory Disclosure

Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures, 2 CFR 200.113 and NIH Grants Policy Statement Section 4.1.36.

Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the HHS Office of Inspector Grant Self Disclosure Program at grantdisclosures@oig.hhs.gov.

Post Submission Materials Applicants are required to follow the instructions for post-submission materials, as described in the policy

Section V. Application Review Information

1. Criteria Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?

Investigator(s)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)?

This is the start of the file's text. The full file is on GovTribe.

Other files

File Type Posted
PKG00294601.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

File details come from the government source that posted it. Updated .